NLRP3 and neoplasm: Nevertheless, the inflammatory pathways are also affected by immune checkpoint inhibitors, nivolumab and ipilimumab, that caused changes in NLRP3 inflammasome, MyD88 complex NF-κB/p65 expression, and in several interleukins in co-cultures of lymphocytes with tumor or with cardiac cells.